• Follow
NovaRock Biotheraputics
  • Home
  • About
  • Pipeline
  • Innovation
  • Careers
  • News
  • Home
  • About
  • Pipeline
  • Innovation
  • Careers
  • News
  • Follow
News

NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases

Ewing, NJ, January 6, 2021 – NovaRock Biotherapeutics Ltd, announced today that the U.S. Food and Drug Administration (FDA) has […]

Read More

NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Pancreatic Cancer

Ewing, NJ, December 3, 2020 – NovaRock Biotherapeutics Ltd, announced today that their investigational new drug, NBL-015, has been granted […]

Read More
NovaRock Biotheraputics © NovaRock Biotherapeutics Inc. All rights reserved. | Sitemap